XPhyto Therapeutics Corp has announced that Dr Florian A. Sahr, a German-born and internationally-trained leader in drug formulation, technology transfer and new-product manufacturing, has joined its European operations as head of project management.
The company noted that Dr Sahr has a strong track record in drug development, including transdermal (TDS) and oral dissolvable (ODF) delivery systems, as well as the physical and regulatory establishment of GMP and FDA compliant pharmaceutical manufacturing facilities.
Dr Sahr is engaged full-time at Vektor Pharma TF GmbH, XPhyto's wholly-owned German subsidiary, it added.
READ: XPhyto Therapeutics says advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year
“Dr Sahr's management of Vektor's TDS and ODF product development programs, and his technology transfer skills are highly relevant as XPhyto reviews its ODF novel biosensor manufacturing options and opportunities,” the company said in a statement.
Dr Sahr has held the regulated position of head of manufacturing according to AMG/AMWHV (German Medicines Act) for the production of clinical trial materials for a number of companies, XPhyto added.
Formerly senior scientist and head of manufacturing at Gen-Plus GmbH & Co. KG in Munich, Germany, Dr Sahr developed TDS and ODF drug formulations and transferred these new formulations and technologies to its manufacturing systems and facilities.
He was also project manager of advanced projects at tesa Labtec GmbH in Langenfeld, Germany, focusing on project management and technology transfer of generic TDS formulations to the company's manufacturing facilities.
XPhyto is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions.
The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
Contact the author at jon.hopkins@proactiveinvestors.com